Skip to main content
Premium Trial:

Request an Annual Quote

Expression Analysis Teams with Illumina, Golden Helix on Grant Program

Premium

Expression Analysis announced yesterday that it has teamed up with Illumina and Golden Helix on an RNA-seq grant program.

Under the program, Expression Analysis will perform the sequencing and provide primary and secondary data analysis, while Golden Helix will provide cloud-based secondary analysis tools and storage as well as end-user tertiary analysis tools. Illumina will provide the products for the studies, Expression Analysis said.

One grant will be awarded for each category: biomarker discovery using whole-transcriptome sequencing; developmental coding and non-coding RNA expression; and RNA-seq analysis of FFPE samples.

Applications for the grants are due April 13, and recipients will be notified no later than May 15. More information about the grant program can be found on Expression Analysis' website.

The Scan

Rare Genetic Disease Partnership

A public-private partnership plans to speed the development of gene therapies for rare genetic diseases, Stat News writes.

Approval Sought for Alzheimer's Drug

The Wall Street Journal reports Eli Lilly has initiated a rolling submission to the US Food and Drug Administration to seek approval for its drug to treat Alzheimer's disease.

DNA Barcoding Paper Retracted

Science reports that a 2014 DNA barcoding paper was retracted after a co-author brought up data validity concerns.

Nature Papers Present Genomic Analysis of Bronze Age Mummies, Approach to Study Host-Pathogen Interactions

In Nature this week: analysis finds Tarim mummies had local genetic origin, and more.